ReviewCurrent hypertension reports2018
Cardiovascular Risk in Patients with Prehypertension and the Metabolic Syndrome.
Review in Current hypertension reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 40 citations in OpenAlex.
- Cardiovascular Diseases and All-Cause Mortality Risk in Patients With Prehypertension and Noncommunicable Diseases: Results From the Kailuan Study.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- Lipid Metabolic Mediators Bridge Ischemic Heart Disease and Amyotrophic Lateral Sclerosis.Molecular neurobiology · 2026Article
- Coronary Microvascular Dysfunction in Ischaemic Heart Disease: Lessons From Large Animal Models.Basic & clinical pharmacology & toxicology · 2025Review
- Article
- Coronary Microvascular Dysfunction: Insights on Prognosis and Future Perspectives.Reviews in cardiovascular medicine · 2025Review
- Arterial stiffness and biochemical profiles in prehypertensive, normotensive, and controlled hypertensive individuals: a cross-sectional study.Frontiers in cardiovascular medicine · 2025Article
- The Association of the Metabolic Score for Insulin Resistance (METS-IR) with Prehypertension in Normoglycemic Individuals.International journal of endocrinology and metabolism · 2024Article
- Specific gut microbiota may increase the risk of erectile dysfunction: a two-sample Mendelian randomization study.Frontiers in endocrinology · 2023Article
- Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options.Biomedicines · 2022Review
- Comparison of the Mediterranean diet and the Dietary Approach Stop Hypertension in reducing the risk of 10-year fatal and non-fatal CVD events in healthy adults: the ATTICA Study (2002-2012).Public health nutrition · 2021Article
- Body roundness index is a superior indicator to associate with the cardio-metabolic risk: evidence from a cross-sectional study with 17,000 Eastern-China adults.BMC cardiovascular disorders · 2021Article
- Mechanobiology of Microvascular Function and Structure in Health and Disease: Focus on the Coronary Circulation.Frontiers in physiology · 2021Review
- The Controversial Role of Human Gut Lachnospiraceae.Microorganisms · 2020Review
- ESC Working Group on Coronary Pathophysiology and Microcirculation position paper on 'coronary microvascular dysfunction in cardiovascular disease'.Cardiovascular research · 2020Review
- Oxidative Stress in Ischemic Heart Disease.Oxidative medicine and cellular longevity · 2020Review
- The Relationship between Risk Factors for Metabolic Syndrome and Bone Mineral Density in Menopausal Korean Women.Iranian journal of public health · 2019Article
- Stage 1 hypertension, but not elevated blood pressure, predicts 10-year fatal and non-fatal CVD events in healthy adults: the ATTICA Study.Journal of human hypertension · 2019Article
- Identifying the Impact of Metabolic Syndrome in Hypertensive Patients.Arquivos brasileiros de cardiologia · 2018Article
- Valsartan Alleviates Insulin Resistance in Skeletal Muscle of Chronic Renal Failure Rats.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Systemic and specific effects of antihypertensive and lipid-lowering medication on plasma protein biomarkers for cardiovascular diseases.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prehypertension (pHTN) and metabolic syndrome (MetS) are both lifestyle diseases that are potentiated by increased adiposity, as both disease processes are closely related to weight. In the case of pHTN, increased adiposity causes dysregulation of the renin-angiotensin-aldosterone-system (RAAS) as well as adipokine- and leptin-associated increases in adrenergic tone. In MetS, excess weight potentiates hyperglycemia and insulin resistance which causes positive feedback into the RAAS system, activates an inflammatory cascade that potentiates atherosclerosis, and causes lipid dysregulation which together contribute to cardiovascular disease, especially coronary heart disease (CHD) and heart failure (HF). The relationship with all-cause mortality is not as clear-cut in part because of some protective effects associated with the obesity paradox in chronic diseases such as CHD and HF. However, in healthy populations, the absence of excess weight and its associated effects on prehypertension and MetS are associated with a longer absolute and disease-free lifespan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.